#1 Clinical Trials Search in Europe

Tazobactam Sodium

Tazobactam Sodium, often used in combination with other antibiotics, is being studied in various clinical trials to assess its effectiveness in treating different types of infections. These trials aim to evaluate the drug’s efficacy, safety, and pharmacokinetics in diverse patient populations, including those with hematologic cancers, diabetic foot infections, and complicated intra-abdominal infections. The research also extends to pregnant women and neonates at risk of early-onset sepsis.

Table of Contents

What is Tazobactam Sodium?

Tazobactam Sodium is an antibiotic medication used to treat various bacterial infections. It belongs to a class of drugs called beta-lactamase inhibitors. Tazobactam Sodium is not typically used alone but is combined with other antibiotics to enhance their effectiveness[1].

How Tazobactam Sodium Works

Tazobactam Sodium works by preventing bacteria from breaking down certain antibiotics. This allows the antibiotic to work more effectively against the infection. When combined with antibiotics like piperacillin, it creates a powerful combination that can fight a wide range of bacterial infections[2].

Medical Conditions Treated

Tazobactam Sodium, when combined with other antibiotics, is used to treat various conditions, including:

  • Complicated intra-abdominal infections: These are infections that occur within the abdomen and can be life-threatening if not treated promptly[4].
  • Diabetic foot infections: These are serious infections that can occur in people with diabetes, often leading to complications if not treated effectively[2].
  • Infections in patients with low white blood cell counts: This includes patients with conditions like leukemia, lymphoma, or those undergoing cancer treatments[1].
  • Early-onset neonatal sepsis: This is a severe infection that can occur in newborns shortly after birth[3].

Combination Therapy

Tazobactam Sodium is most commonly used in combination with other antibiotics. The most frequent combination is with piperacillin, known as piperacillin/tazobactam. This combination is sometimes referred to by the brand name Tazocin™[2]. The combination of these two medications allows for a broader spectrum of antibiotic activity, making it effective against a wider range of bacteria.

How Tazobactam Sodium is Administered

Tazobactam Sodium is typically administered intravenously (IV), which means it’s given directly into a vein. The dosage and duration of treatment can vary depending on the type and severity of the infection. For example:

  • In some cases, it may be given every 6 hours[1].
  • In other cases, such as for diabetic foot infections, it might be administered every 8 hours[2].
  • The duration of treatment can range from 5 to 28 days, depending on the infection being treated[2].

Clinical Trials and Research

Tazobactam Sodium has been the subject of several clinical trials to evaluate its effectiveness and safety. These studies have compared it to other antibiotics and investigated its use in various patient populations:

  • A study compared piperacillin/tazobactam with and without vancomycin in patients with hematologic cancer and persistent fever[1].
  • Another trial compared ertapenem to piperacillin/tazobactam in treating diabetic foot infections[2].
  • Research has also been conducted on the use of piperacillin/tazobactam in pregnant women and newborns at high risk of developing early-onset sepsis[3].

Potential Side Effects and Safety

Like all medications, Tazobactam Sodium can cause side effects. In clinical trials, researchers monitored for various adverse events (AEs):

  • Adverse Events (AEs): These are any unfavorable changes in health that occur during treatment, whether or not they are related to the medication[2].
  • Drug-related AEs: These are side effects that are believed to be caused by the medication[2].
  • Serious AEs (SAEs): These are more severe side effects that may require medical intervention or hospitalization[2].

It’s important to note that not everyone experiences side effects, and the benefits of treatment often outweigh the risks. Always discuss any concerns with your healthcare provider.

Aspect Details
Drug Combinations Tazobactam Sodium is often combined with Piperacillin or other antibiotics
Administration Method Typically given intravenously (IV)
Treatment Duration Varies by study, ranging from 5 to 28 days
Conditions Studied Hematologic cancer-related infections, diabetic foot infections, early-onset neonatal sepsis, complicated intra-abdominal infections
Patient Populations Adults with various infections, pregnant women, neonates at risk of sepsis
Primary Outcomes Clinical response, microbiological response, pharmacokinetic parameters
Safety Monitoring Adverse events, serious adverse events, drug-related adverse events

FAQ

  • What is Tazobactam Sodium used for in clinical trials? Tazobactam Sodium is being studied in combination with other antibiotics to treat various infections, including those in patients with hematologic cancers, diabetic foot infections, and complicated intra-abdominal infections. It's also being investigated for use in pregnant women and neonates at risk of early-onset sepsis.
  • How is Tazobactam Sodium administered in these trials? In the trials, Tazobactam Sodium is typically administered intravenously (IV). For example, in one study, piperacillin/tazobactam was given as 4.5g IV every 8 hours, infused over 30 minutes.
  • What are some of the conditions being studied with Tazobactam Sodium? The conditions being studied include persistent fever in patients with hematologic cancers, diabetic foot infections, early-onset neonatal sepsis, and complicated intra-abdominal infections.
  • Are there any side effects associated with Tazobactam Sodium in these trials? While specific side effects aren't detailed in the provided information, the trials are monitoring for adverse events (AEs) and drug-related AEs. Some studies are specifically measuring the percentage of participants experiencing AEs, serious AEs, and those who discontinue treatment due to AEs.
  • How long do the treatments with Tazobactam Sodium typically last in these trials? The duration of treatment varies depending on the specific trial and condition being treated. For example, in some studies, treatment lasted from 5 to 28 days, while others mentioned an average study duration of about 20 days.

Ongoing Clinical Trials on Tazobactam Sodium

  • Comparing pivmecillinam and gentamicin with standard treatments for hospitalized adults with complicated urinary tract infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway Sweden

  • Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on Early Stopping of Antibiotics in Elderly Patients with Viral Infections Using Amoxicillin, Clavulanic Acid, Piperacillin, Tazobactam, and Pristinamycin

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Piperacillin/Tazobactam and Levofloxacin for Patients with COPD or Cystic Fibrosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Antibiotic Prophylaxis with Piperacillin, Tazobactam, and Cefazolin for Burn Patients Undergoing Excision-Graft Surgery

    Recruiting

    3 1 1
    Investigated drugs:
    France

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Post-Surgery Antibiotic Use for Patients with Biliary Stents Undergoing Pancreaticoduodenectomy: Piperacillin and Tazobactam Evaluation

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Piperacillin-Tazobactam and Temocillin for Treating Severe Infections in ICU Patients with ESBL-Producing Gram-Negative Bacteria

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Tazobactam Sodium: An antibiotic often used in combination with other drugs to treat various types of bacterial infections.
  • Piperacillin: An antibiotic often combined with Tazobactam to create a more effective treatment against certain bacterial infections.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Granulocytopenia: A condition where there is a lower than normal number of granulocytes, a type of white blood cell important for fighting infections.
  • Early-Onset Sepsis: A serious bacterial infection that occurs in newborns, typically within the first 72 hours of life.
  • Pharmacokinetic: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or is otherwise medically significant.
  • Microbiologically evaluable: Patients in a study whose infection-causing bacteria can be identified and studied to determine the effectiveness of the antibiotic treatment.
  • Pharmacodynamic: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of their actions.

References

  1. https://clinicaltrials.gov/study/NCT00003805
  2. https://clinicaltrials.gov/study/NCT01370616
  3. https://clinicaltrials.gov/study/NCT06076200
  4. https://clinicaltrials.gov/study/NCT00389987